Cardiomyopathies, often inherited heart conditions, are gaining prominence as traditional cardiovascular disease prevention improves. As strategies to prevent common heart ailments become more effective, conditions with largely non-modifiable mechanisms – like cardiomyopathies – represent a growing proportion of overall cardiovascular disease burden. This shift highlights an urgent need for faster access to innovative medications for patients suffering from these conditions. Cardiomyopathies are becoming increasingly relevant in the context of overall cardiovascular health. The increasing prevalence underscores the importance of focusing research and resources on these less-preventable heart diseases. Experts emphasize the necessity of rapid access to new therapies to address this evolving challenge. Further investigation and treatment options are crucial for improving patient outcomes.